[1] Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.
